AstraZeneca Datroway Wins EU Approval, 5-Month OS Gain
See more from StockTitan in Google Search…
AstraZeneca wins EU approval for Datroway in TNBC | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
AstraZeneca reports Sone-Ve boosts gastric cancer survival | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
AstraZeneca H1 Results: $30.7B Revenue, Core EPS Up 12%
See more from StockTitan in Google Search…
AstraZeneca updates Ultomiris HSCT-TMA Phase III data | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
AstraZeneca posts H1 2026 revenue of $30.7B | AZN SEC Filing
Sustainability Sustainability highlights AstraZeneca received several prestigious recognitions for its sustainability leadership in the quarter. TIME Magazine named…
AstraZeneca Enhertu EU Approval Recommendation, 44% Risk Cut
Key Terms
chmp
regulatory
The CHMP is the European Medicines…
AstraZeneca gets EU nod for Etcamah in breast cancer | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
AstraZeneca licenses lung cancer drug Zegfrovy | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
AstraZeneca officer granted shares under incentive plan
SEC Form 4 FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP…
Abbisko, AstraZeneca to test lumipodlin with Tagrisso
SHANGHAI, July 1, 2026 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter, HKEX code: 02256.HK) today announced…
AstraZeneca updates total voting rights for June 2026 | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…